Brokerage Firm Rating Update on Palatin Technologies (PTN)

Palatin Technologies (PTN) : Zacks Investment Research ranks Palatin Technologies (PTN) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 2 research analysts is 1, which indicates as a Strong Buy.


For the current week, the company shares have a recommendation consensus of Buy.

Palatin Technologies (NYSEMKT:PTN): The stock opened at $0.53 and touched an intraday high of $0.53 on Wednesday. During the day, the stock corrected to an intraday low of $0.5001, however, the bulls stepped in and pushed the price higher to close in the green at $0.5083 with a gain of 0.65% for the day. The total traded volume for the day was 554,049. The stock had closed at $0.505 in the previous trading session.

Palatin Technologies, Inc. is a biopharmaceutical company that develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. The Companys programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in clinical development is Bremelanotide, which is used for the treatment of female sexual dysfunction (FSD). In addition, the Company has drug candidates or development programs for obesity, erectile dysfunction, cardiovascular diseases, pulmonary diseases, inflammatory diseases and dermatologic diseases. Its other drug development programs include Melanocortin receptor-4 (MC4r); PL-3994, and Melanocortin receptor-1 (MC1r). It is developing other Melanocortin drug discovery programs in the melanocortin field, primarily developing peptide compounds, including MC1r agonists, and peptides specific for MC4r, including both agonists and antagonists.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.